Gilead Sciences

What the published record states about identity, evidence, evaluation, monitoring, authority, and freshness. Watched-source schedules are not published for this record.

• Identityunclaimed
  Published
• Evidencesource_reported
  Published
• Evaluationnot_evaluated
  Published
• MonitoringNot yet published for this record.
  Not published
• AuthorityNot yet published for this record.
  Not published
• Freshnesscurrent
  Published

9 directors published. 8 of 9 with a published determination are independent.

Who can act for the company, and on whose authority. This is what a counterparty's agent checks before it accepts an order, signs, or pays.

Published Claims that belong to no section above. Each keeps its permalink, evidence, and assertion state.

A gap is a coverage state, not a negative finding. These sections are expected for this entity class and are not yet published.

• Corporate structureNot reviewed. Parent, subsidiary and predecessor structure explains who is governed.
• OwnershipNot reviewed. Ownership and voting power determine who can influence the board.
• FinancialsNot reviewed. Governance-relevant financial context frames capital and audit decisions.
• CompensationNot reviewed. Pay design shows how incentives are governed.
• GovernanceNot reviewed. Governing documents and provisions set the rules of the enterprise.
• Shareholder governanceNot reviewed. Meeting and vote records show shareholder dissent and support.
• AuditNot reviewed. Auditor, controls and restatements show assurance over reporting.
• LegalNot reviewed. Material legal and regulatory matters show enforcement exposure.
• RiskNot reviewed. Risk ownership links the board, committees, executives and controls.
• CyberNot reviewed. Cyber and data governance is a disclosed oversight domain.
• AI governanceNot reviewed. AI oversight is a differentiated Alpha governance domain.
• Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.
• Only explicitly published canonical company identity and current confirmed public roles are included.Only explicitly published canonical company identity and current confirmed public roles are included.
• Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.
• Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.
• This Company Profile is an identity and evidence record, not an Alpha rating.This Company Profile is an identity and evidence record, not an Alpha rating.

• AD
  Andrew D. DickinsonChief Financial Officer
  company:df907e92-42eb-4543-9f1d-c2a9727ef16e:leadership_role:18
• DP
  Daniel P. ODayChairman and Chief Executive Officer
  company:df907e92-42eb-4543-9f1d-c2a9727ef16e:leadership_role:20, company:df907e92-42eb-4543-9f1d-c2a9727ef16e:leadership_role:9
• DB
  Dietmar BergerChief Medical Officer
  company:df907e92-42eb-4543-9f1d-c2a9727ef16e:leadership_role:21
• JM
  Johanna MercierChief Commercial and Corporate Affairs Officer
  company:df907e92-42eb-4543-9f1d-c2a9727ef16e:leadership_role:22
• KM
  Keeley M. Cain WettanExecutive Vice President, General Counsel, Legal and Compliance
  company:df907e92-42eb-4543-9f1d-c2a9727ef16e:leadership_role:23
• DP
  Daniel P. O'DayChairman and Chief Executive Officer
  company:df907e92-42eb-4543-9f1d-c2a9727ef16e:leadership_role:19
• AW
  Anthony WeltersLead Independent Director
  company:df907e92-42eb-4543-9f1d-c2a9727ef16e:leadership_role:10
• HM
  Harish ManwaniIndependent Director
  company:df907e92-42eb-4543-9f1d-c2a9727ef16e:leadership_role:11
• JK
  Jacqueline K. BartonIndependent Director
  company:df907e92-42eb-4543-9f1d-c2a9727ef16e:leadership_role:12
• JJ
  Javier J. RodriguezIndependent Director
  company:df907e92-42eb-4543-9f1d-c2a9727ef16e:leadership_role:13
• JA
  Jeffrey A. BluestoneIndependent Director
  company:df907e92-42eb-4543-9f1d-c2a9727ef16e:leadership_role:14
• KA
  Kelly A. KramerIndependent Director
  company:df907e92-42eb-4543-9f1d-c2a9727ef16e:leadership_role:15
• SJ
  Sandra J. HorningIndependent Director
  company:df907e92-42eb-4543-9f1d-c2a9727ef16e:leadership_role:16
• TW
  Ted W. LoveIndependent Director
  company:df907e92-42eb-4543-9f1d-c2a9727ef16e:leadership_role:17

This record exists because the company is in the published Registry. The company can claim the record, correct, or dispute any Claim. Corrections are versioned and the original stays in history.

Basis

Published company record built from public sources

Sources

12 evidence records cited. 0 with redistribution rights.

Never published

Private enterprise overlay data: deployments, authority grants, TrustChecks, receipts, telemetry

Record claimed

No

Open disputes

0

Identity ownership

unclaimed

If the company claims the record, its statements appear as their own assertion state and never overwrite the cited evidence.

1. E1
   Alpha canonical company public projection

   Alpha canonical company public projection. canonical identity. Retrieved Oct 15, 2026. Cited by 6 Claims.
   Open web
   Rights not recorded, link only
   Evidence not pinned
2. E2
   GILEAD SCIENCES, INC. Form 10-K (filed 2026-02-24)

   GILEAD SCIENCES, INC. Form 10-K (filed 2026-02-24). SEC filing. Retrieved Aug 29, 2026. Cited by 2 Claims.
   Authoritative, regulatory filing
   Rights not recorded, link only
   Evidence not pinned
3. E3
   Gilead Sciences, Inc. DEF 14A 2026-03-20

   sec proxy. Published Mar 20, 2026. Retrieved Mar 23, 2026. Cited by 9 Claims.
   Authoritative, regulatory filing
   Rights not recorded, link only
   Evidence not pinned
4. E4
   GILD 10-K executive officers

   sec filing. Published Feb 24, 2026. Retrieved May 4, 2026. Cited by 1 Claim.
   Authoritative, regulatory filing
   Rights not recorded, link only
   Evidence not pinned
5. E5
   GILD executive roster source

   sec filing. Published May 3, 2026. Retrieved May 3, 2026. Cited by 1 Claim.
   Authority not assessed
   Rights not recorded, link only
   Evidence not pinned
6. E6
   GILD 10-K executive officers

   sec filing. Published Feb 24, 2026. Retrieved May 4, 2026. Cited by 1 Claim.
   Authoritative, regulatory filing
   Rights not recorded, link only
   Evidence not pinned
7. E7
   GILD 10-K executive officers

   sec filing. Published Feb 24, 2026. Retrieved May 4, 2026. Cited by 1 Claim.
   Authoritative, regulatory filing
   Rights not recorded, link only
   Evidence not pinned
8. E8
   GILD 10-K executive officers

   sec filing. Published Feb 24, 2026. Retrieved May 4, 2026. Cited by 1 Claim.
   Authoritative, regulatory filing
   Rights not recorded, link only
   Evidence not pinned
9. E9
   GILD 10-K executive officers

   sec filing. Published Feb 24, 2026. Retrieved May 4, 2026. Cited by 1 Claim.
   Authoritative, regulatory filing
   Rights not recorded, link only
   Evidence not pinned
10. E10
    Audit

    board_seats. sp500-board-director-completeness-remediation-2026-05-15. Cited by 13 Claims.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
11. E11
    S&P 500

    Slickcharts S&P 500 constituent table (public observation, not S&P DJI license). index provider. Retrieved Sep 2, 2026. Cited by 1 Claim.
    Open web
    Rights not recorded, link only
    Evidence not pinned
12. E12
    Nasdaq-100

    Nasdaq official Nasdaq-100 list-type API. index provider. Retrieved Sep 2, 2026. Cited by 1 Claim.
    Open web
    Rights not recorded, link only
    Evidence not pinned

• Andrew D. Dickinson executive of Gilead Sciences, effective 2026-02-24.
• Daniel P. ODay executive of Gilead Sciences, effective 2026-02-24.
• Dietmar Berger executive of Gilead Sciences, effective 2026-02-24.
• Johanna Mercier executive of Gilead Sciences, effective 2026-02-24.
• Keeley M. Cain Wettan executive of Gilead Sciences, effective 2026-02-24.
• Ted W. Love seat on Gilead Sciences, effective 2024-01-01.
• Anthony Welters seat on Gilead Sciences, effective 2020-01-01.
• Anthony Welters lead independent director of Gilead Sciences, effective 2020-01-01.
• Javier J. Rodriguez seat on Gilead Sciences, effective 2020-01-01.
• Jeffrey A. Bluestone seat on Gilead Sciences, effective 2020-01-01.
• Sandra J. Horning seat on Gilead Sciences, effective 2020-01-01.
• Javier J. Rodriguez member of Audit, effective 2020-01-01.
• Compensation and Talent · Chair; Nominating and Corporate Governance committee of Gilead Sciences, effective 2020-01-01.
• Anthony Welters member of Compensation and Talent · Chair; Nominating and Corporate Governance, effective 2020-01-01.
• Daniel P. ODay seat on Gilead Sciences, effective 2019-01-01.
• Daniel P. ODay chairs board Gilead Sciences, effective 2019-01-01.
• Harish Manwani seat on Gilead Sciences, effective 2018-01-01.
• Jacqueline K. Barton seat on Gilead Sciences, effective 2018-01-01.
• Compensation and Talent; Nominating and Corporate Governance · Chair committee of Gilead Sciences, effective 2018-01-01.
• Harish Manwani member of Compensation and Talent; Nominating and Corporate Governance · Chair, effective 2018-01-01.
• Kelly A. Kramer seat on Gilead Sciences, effective 2016-01-01.
• Audit · Chair; Compensation and Talent committee of Gilead Sciences, effective 2016-01-01.
• Kelly A. Kramer member of Audit · Chair; Compensation and Talent, effective 2016-01-01.